Literature DB >> 19193811

Quantitating the multiplicity of infection with human immunodeficiency virus type 1 subtype C reveals a non-poisson distribution of transmitted variants.

M-R Abrahams1, J A Anderson, E E Giorgi, C Seoighe, K Mlisana, L-H Ping, G S Athreya, F K Treurnicht, B F Keele, N Wood, J F Salazar-Gonzalez, T Bhattacharya, H Chu, I Hoffman, S Galvin, C Mapanje, P Kazembe, R Thebus, S Fiscus, W Hide, M S Cohen, S Abdool Karim, B F Haynes, G M Shaw, B H Hahn, B T Korber, R Swanstrom, C Williamson.   

Abstract

Identifying the specific genetic characteristics of successfully transmitted variants may prove central to the development of effective vaccine and microbicide interventions. Although human immunodeficiency virus transmission is associated with a population bottleneck, the extent to which different factors influence the diversity of transmitted viruses is unclear. We estimate here the number of transmitted variants in 69 heterosexual men and women with primary subtype C infections. From 1,505 env sequences obtained using a single genome amplification approach we show that 78% of infections involved single variant transmission and 22% involved multiple variant transmissions (median of 3). We found evidence for mutations selected for cytotoxic-T-lymphocyte or antibody escape and a high prevalence of recombination in individuals infected with multiple variants representing another potential escape pathway in these individuals. In a combined analysis of 171 subtype B and C transmission events, we found that infection with more than one variant does not follow a Poisson distribution, indicating that transmission of individual virions cannot be seen as independent events, each occurring with low probability. While most transmissions resulted from a single infectious unit, multiple variant transmissions represent a significant fraction of transmission events, suggesting that there may be important mechanistic differences between these groups that are not yet understood.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19193811      PMCID: PMC2663249          DOI: 10.1128/JVI.02132-08

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  Recombination: Multiply infected spleen cells in HIV patients.

Authors:  Andreas Jung; Reinhard Maier; Jean-Pierre Vartanian; Gennady Bocharov; Volker Jung; Ulrike Fischer; Eckart Meese; Simon Wain-Hobson; Andreas Meyerhans
Journal:  Nature       Date:  2002-07-11       Impact factor: 49.962

2.  Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission.

Authors:  Cynthia A Derdeyn; Julie M Decker; Frederic Bibollet-Ruche; John L Mokili; Mark Muldoon; Scott A Denham; Marintha L Heil; Francis Kasolo; Rosemary Musonda; Beatrice H Hahn; George M Shaw; Bette T Korber; Susan Allen; Eric Hunter
Journal:  Science       Date:  2004-03-26       Impact factor: 47.728

3.  Gender differences in HIV-1 diversity at time of infection.

Authors:  E M Long; H L Martin; J K Kreiss; S M Rainwater; L Lavreys; D J Jackson; J Rakwar; K Mandaliya; J Overbaugh
Journal:  Nat Med       Date:  2000-01       Impact factor: 53.440

4.  Route of simian immunodeficiency virus inoculation determines the complexity but not the identity of viral variant populations that infect rhesus macaques.

Authors:  J L Greenier; C J Miller; D Lu; P J Dailey; F X Lü; K J Kunstman; S M Wolinsky; M L Marthas
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

5.  Modeling plasma virus concentration during primary HIV infection.

Authors:  M A Stafford; L Corey; Y Cao; E S Daar; D D Ho; A S Perelson
Journal:  J Theor Biol       Date:  2000-04-07       Impact factor: 2.691

6.  A novel antiviral intervention results in more accurate assessment of human immunodeficiency virus type 1 replication dynamics and T-cell decay in vivo.

Authors:  Martin Markowitz; Michael Louie; Arlene Hurley; Eugene Sun; Michele Di Mascio; Alan S Perelson; David D Ho
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

7.  Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection.

Authors:  Eberhard W Fiebig; David J Wright; Bhupat D Rawal; Patricia E Garrett; Richard T Schumacher; Lorraine Peddada; Charles Heldebrant; Richard Smith; Andrew Conrad; Steven H Kleinman; Michael P Busch
Journal:  AIDS       Date:  2003-09-05       Impact factor: 4.177

8.  Identification of modifiable factors that affect the genetic diversity of the transmitted HIV-1 population.

Authors:  Manish Sagar; Ludo Lavreys; Jared M Baeten; Barbra A Richardson; Kishorchandra Mandaliya; Jeckoniah O Ndinya-Achola; Joan K Kreiss; Julie Overbaugh
Journal:  AIDS       Date:  2004-03-05       Impact factor: 4.177

9.  Infection with multiple human immunodeficiency virus type 1 variants is associated with faster disease progression.

Authors:  Manish Sagar; Ludo Lavreys; Jared M Baeten; Barbra A Richardson; Kishorchandra Mandaliya; Bhavna H Chohan; Joan K Kreiss; Julie Overbaugh
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  Dual HIV-1 infection associated with rapid disease progression.

Authors:  Geoffrey S Gottlieb; David C Nickle; Mark A Jensen; Kim G Wong; Jandre Grobler; Fusheng Li; Shan-Lu Liu; Cecilia Rademeyer; Gerald H Learn; Salim S Abdool Karim; Carolyn Williamson; Lawrence Corey; Joseph B Margolick; James I Mullins
Journal:  Lancet       Date:  2004-02-21       Impact factor: 79.321

View more
  246 in total

1.  Detection of minority resistance during early HIV-1 infection: natural variation and spurious detection rather than transmission and evolution of multiple viral variants.

Authors:  Sara Gianella; Wayne Delport; Mary E Pacold; Jason A Young; Jun Yong Choi; Susan J Little; Douglas D Richman; Sergei L Kosakovsky Pond; Davey M Smith
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  For protection from HIV-1 infection, more might not be better: a systematic analysis of HIV Gag epitopes of two alleles associated with different outcomes of HIV-1 infection.

Authors:  Ma Luo; Christina A Daniuk; Tamsir O Diallo; Rupert E Capina; Joshua Kimani; Charles Wachihi; Makubo Kimani; Thomas Bielawny; Trevor Peterson; Mark G R Mendoza; Sandra Kiazyk; T Blake Ball; Francis A Plummer
Journal:  J Virol       Date:  2011-11-09       Impact factor: 5.103

3.  Source identification in two criminal cases using phylogenetic analysis of HIV-1 DNA sequences.

Authors:  Diane I Scaduto; Jeremy M Brown; Wade C Haaland; Derrick J Zwickl; David M Hillis; Michael L Metzker
Journal:  Proc Natl Acad Sci U S A       Date:  2010-11-15       Impact factor: 11.205

4.  Short communication decreased incidence of dual infections in South african subtype C-infected women compared to a cohort ten years earlier.

Authors:  Zenda Woodman; Koleka Mlisana; Florette Treurnicht; Melissa-Rose Abrahams; Ruwayida Thebus; Salim Abdool Karim; Carolyn Williamson
Journal:  AIDS Res Hum Retroviruses       Date:  2011-02-09       Impact factor: 2.205

5.  Primary infection by a human immunodeficiency virus with atypical coreceptor tropism.

Authors:  Chunlai Jiang; Nicholas F Parrish; Craig B Wilen; Hui Li; Yue Chen; Jeffrey W Pavlicek; Anna Berg; Xiaozhi Lu; Hongshuo Song; John C Tilton; Jennifer M Pfaff; Elizabeth A Henning; Julie M Decker; M Anthony Moody; Mark S Drinker; Robert Schutte; Stephanie Freel; Georgia D Tomaras; Rebecca Nedellec; Donald E Mosier; Barton F Haynes; George M Shaw; Beatrice H Hahn; Robert W Doms; Feng Gao
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

6.  The Thai Phase III HIV Type 1 Vaccine trial (RV144) regimen induces antibodies that target conserved regions within the V2 loop of gp120.

Authors:  Nicos Karasavvas; Erik Billings; Mangala Rao; Constance Williams; Susan Zolla-Pazner; Robert T Bailer; Richard A Koup; Sirinan Madnote; Duangnapa Arworn; Xiaoying Shen; Georgia D Tomaras; Jeffrey R Currier; Mike Jiang; Craig Magaret; Charla Andrews; Raphael Gottardo; Peter Gilbert; Timothy J Cardozo; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Punnee Pitisuttithum; Jaranit Kaewkungwal; Robert Paris; Kelli Greene; Hongmei Gao; Sanjay Gurunathan; Jim Tartaglia; Faruk Sinangil; Bette T Korber; David C Montefiori; John R Mascola; Merlin L Robb; Barton F Haynes; Viseth Ngauy; Nelson L Michael; Jerome H Kim; Mark S de Souza
Journal:  AIDS Res Hum Retroviruses       Date:  2012-10-04       Impact factor: 2.205

7.  Characterization of the Transmitted Virus in an Ongoing HIV-1 Epidemic Driven by Injecting Drug Use.

Authors:  Elena Dukhovlinova; Alexey Masharsky; Aleksandra Vasileva; Alessandro Porrello; Shuntai Zhou; Olga Toussova; Sergei Verevochkin; Ekaterina Akulova; Dmitrij Frishman; David Montefiori; Celia Labranche; Irving Hoffman; William Miller; Myron S Cohen; Andrei P Kozlov; Ronald Swanstrom
Journal:  AIDS Res Hum Retroviruses       Date:  2018-07-30       Impact factor: 2.205

8.  Cervicovaginal Inflammation Facilitates Acquisition of Less Infectious HIV Variants.

Authors:  Philippe Selhorst; Lindi Masson; Sherazaan D Ismail; Natasha Samsunder; Nigel Garrett; Leila E Mansoor; Quarraisha Abdool Karim; Salim S Abdool Karim; Jo-Ann S Passmore; Carolyn Williamson
Journal:  Clin Infect Dis       Date:  2016-09-29       Impact factor: 9.079

Review 9.  Compartmentalization, Viral Evolution, and Viral Latency of HIV in the CNS.

Authors:  Maria M Bednar; Christa Buckheit Sturdevant; Lauren A Tompkins; Kathryn Twigg Arrildt; Elena Dukhovlinova; Laura P Kincer; Ronald Swanstrom
Journal:  Curr HIV/AIDS Rep       Date:  2015-06       Impact factor: 5.071

10.  A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays.

Authors:  Matthias H Kraus; Nicholas F Parrish; Katharina S Shaw; Julie M Decker; Brandon F Keele; Jesus F Salazar-Gonzalez; Truman Grayson; David T McPherson; Li-Hua Ping; Jeffrey A Anderson; Ronald Swanstrom; Carolyn Williamson; George M Shaw; Beatrice H Hahn
Journal:  Virology       Date:  2009-12-08       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.